Predictions
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€726.70
01.05.24
01.05.24
€936.94
01.05.25
01.05.25
14.05%
21.06.24
21.06.24
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€41.10
01.05.24
01.05.24
-
01.05.25
01.05.25
-4.61%
21.06.24
21.06.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€726.70
01.05.24
01.05.24
€842.40
01.05.25
01.05.25
14.05%
21.06.24
21.06.24
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€60.80
01.05.24
01.05.24
€79.54
01.05.25
01.05.25
9.87%
21.06.24
21.06.24
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€60.80
01.05.24
01.05.24
€79.54
01.05.25
01.05.25
9.87%
21.06.24
21.06.24
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€60.80
01.05.24
01.05.24
€79.54
01.05.25
01.05.25
9.87%
21.06.24
21.06.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€726.70
01.05.24
01.05.24
€834.73
01.05.25
01.05.25
14.05%
21.06.24
21.06.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€732.70
30.04.24
30.04.24
€828.45
30.04.25
30.04.25
13.12%
21.06.24
21.06.24
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€835.40
30.04.24
30.04.24
-
30.04.25
30.04.25
17.93%
21.06.24
21.06.24
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€835.40
30.04.24
30.04.24
-
30.04.25
30.04.25
17.93%
21.06.24
21.06.24
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€835.40
30.04.24
30.04.24
-
30.04.25
30.04.25
17.93%
21.06.24
21.06.24
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
28.04.24
28.04.24
-
28.04.25
28.04.25
7.85%
21.06.24
21.06.24
Bad rating
EBIT decline/stagnation expected
Probably not worthwhile Investment
High valuation
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
28.04.24
28.04.24
-
28.04.25
28.04.25
7.85%
21.06.24
21.06.24
Bad rating
EBIT decline/stagnation expected
Probably not worthwhile Investment
High valuation
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
28.04.24
28.04.24
-
28.04.25
28.04.25
7.85%
21.06.24
21.06.24
Bad rating
EBIT decline/stagnation expected
Probably not worthwhile Investment
High valuation